GNOM vs. PSIL

Last updated Jun 4, 2026

GNOM (Global X Genomics & Biotechnology ETF) and PSIL (AdvisorShares Psychedelics ETF) are both Health & Biotech Equities funds. GNOM is passively managed, while PSIL is actively managed. Over the past 3 years, GNOM returned -0.94%/yr vs 9.55%/yr for PSIL. At a 0.49 correlation, their price movements are largely independent. GNOM charges 0.50%/yr vs 1.00%/yr for PSIL.

Performance

GNOM vs. PSIL - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Global X Genomics & Biotechnology ETF (GNOM) and AdvisorShares Psychedelics ETF (PSIL). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, GNOM achieves a 7.81% return, which is significantly lower than PSIL's 20.15% return.

GNOM

• 1D: 1.99%
• 1M: 5.82%
• YTD: 7.81%
• 6M: 6.65%
• 1Y: 54.21%
• 3Y*: -0.94%
• 5Y*: -10.20%
• 10Y*: —

PSIL

• 1D: -2.57%
• 1M: 1.88%
• YTD: 20.15%
• 6M: 23.74%
• 1Y: 65.52%
• 3Y*: 9.55%
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

GNOM vs. PSIL - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021
GNOM Global X Genomics & Biotechnology ETF	7.81%	18.65%	-15.99%	-8.63%	-36.27%	-15.43%
PSIL AdvisorShares Psychedelics ETF	20.15%	74.55%	-19.50%	-25.12%	-67.24%	-41.98%

Correlation

The correlation between GNOM and PSIL is 0.51, which is moderate. They share some common price drivers but move independently often enough to provide real diversification benefit when combined.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.51
Correlation (3Y) Calculated over the trailing 3-year period	0.47
Correlation (All Time) Calculated using the full available price history since Sep 17, 2021	0.49

The correlation between GNOM and PSIL has been stable across timeframes, ranging from 0.47 to 0.51 - a consistent structural relationship.

GNOM vs. PSIL - Sectors Allocation Comparison

Sectors	GNOM	PSIL
Healthcare	99.6%	100.0%
Technology	0.4%	-
Basic Materials	-	-
Communication Services	-	-
Consumer Cyclical	-	-
Consumer Defensive	-	-
Energy	-	-
Financial Services	-	-
Industrials	-	-
Real Estate	-	-
Utilities	-	-

Return for Risk

GNOM vs. PSIL — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

GNOM

GNOM Risk / Return Rank: 57
GNOM Sharpe Ratio Rank: 60
GNOM Sortino Ratio Rank: 61
GNOM Omega Ratio Rank: 53
GNOM Calmar Ratio Rank: 60
GNOM Martin Ratio Rank: 51

PSIL

PSIL Risk / Return Rank: 48
PSIL Sharpe Ratio Rank: 46
PSIL Sortino Ratio Rank: 43
PSIL Omega Ratio Rank: 43
PSIL Calmar Ratio Rank: 66
PSIL Martin Ratio Rank: 43

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

GNOM vs. PSIL - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Global X Genomics & Biotechnology ETF (GNOM) and AdvisorShares Psychedelics ETF (PSIL). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	GNOM	PSIL	Difference
Sharpe ratio: Return per unit of total volatility	2.06	1.58	+0.48
Sortino ratio: Return per unit of downside risk	2.91	2.14	+0.77
Omega ratio: Gain probability vs. loss probability	1.33	1.27	+0.06
Calmar ratio: Return relative to maximum drawdown	3.00	3.23	-0.23
Martin ratio: Return relative to average drawdown	8.62	6.82	+1.80
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

GNOM vs. PSIL - Sharpe Ratio Comparison

The current GNOM Sharpe Ratio is 2.06, which is higher than the PSIL Sharpe Ratio of 1.58. The chart below compares the historical Sharpe Ratios of GNOM and PSIL, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	GNOM	PSIL	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	2.06	1.58	+0.48
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.31	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.09	-0.42	+0.33

Drawdowns

GNOM vs. PSIL - Drawdown Comparison

The maximum GNOM drawdown since its inception was -75.00%, smaller than the maximum PSIL drawdown of -92.72%. Use the drawdown chart below to compare losses from any high point for GNOM and PSIL.

Drawdown Indicators

	GNOM	PSIL	Difference
Max Drawdown Largest peak-to-trough decline	-75.00%	-92.72%	+17.72%
Max Drawdown (1Y) Largest decline over 1 year	-18.17%	-20.38%	+2.21%
Max Drawdown (3Y) Largest decline over 3 years	-46.47%	-64.62%	+18.15%
Max Drawdown (5Y) Largest decline over 5 years	-72.29%	—	—
Current Drawdown Current decline from peak	-55.45%	-76.63%	+21.18%
Average Drawdown Average peak-to-trough decline	-40.55%	-76.76%	+36.21%
Ulcer Index Depth and duration of drawdowns from previous peaks	6.30%	9.63%	-3.33%

Volatility

GNOM vs. PSIL - Volatility Comparison

The current volatility for Global X Genomics & Biotechnology ETF (GNOM) is 8.47%, while AdvisorShares Psychedelics ETF (PSIL) has a volatility of 9.76%. This indicates that GNOM experiences smaller price fluctuations and is considered to be less risky than PSIL based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	GNOM	PSIL	Difference
Volatility (1M) Calculated over the trailing 1-month period	8.47%	9.76%	-1.29%
Volatility (6M) Calculated over the trailing 6-month period	19.44%	27.89%	-8.45%
Volatility (1Y) Calculated over the trailing 1-year period	26.50%	41.80%	-15.30%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	33.57%	63.15%	-29.58%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	34.17%	63.15%	-28.98%

GNOM vs. PSIL - Expense Ratio Comparison

GNOM has a 0.50% expense ratio, which is lower than PSIL's 1.00% expense ratio.

Dividends

GNOM vs. PSIL - Dividend Comparison

GNOM's dividend yield for the trailing twelve months is around 1.27%, less than PSIL's 8.32% yield.

Position	TTM	2025	2024	2023	2022	2021	2020
GNOM Global X Genomics & Biotechnology ETF	1.27%	1.37%	0.00%	0.00%	0.00%	0.03%	0.14%
PSIL AdvisorShares Psychedelics ETF	8.32%	10.95%	1.49%	0.24%	2.91%	0.00%	0.00%

Frequently Asked Questions

Can I hold both GNOM and PSIL in my portfolio?

GNOM and PSIL have a correlation of 0.51, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, GNOM or PSIL?

PSIL has higher volatility (9.76%) compared to GNOM (8.47%). In terms of maximum drawdown, GNOM dropped -75.00% vs PSIL's -92.72%.

Which ETF is better, GNOM or PSIL?

On 3-year performance, PSIL leads with 9.55% vs -0.94% for GNOM. On fees, GNOM is cheaper at 0.50% per year. On volatility, GNOM has been the lower-risk option at 8.47%. The better choice depends on whether you care most about return, fees, risk, or income.

Which ETF has performed better, GNOM or PSIL?

Over the 3-year period, PSIL has performed better with a 9.55% return vs -0.94%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.

Which ETF is cheaper, GNOM or PSIL?

GNOM is cheaper with a 0.50% expense ratio, compared with 1.00% for PSIL.

Which ETF pays a higher dividend yield, GNOM or PSIL?

PSIL has the higher dividend yield at 8.32%, compared with 1.27% for GNOM.

What is the main difference between GNOM and PSIL?

They also come from different issuers: Global X and AdvisorShares. Their fees differ too: 0.50% for GNOM and 1.00% for PSIL.

Which has better risk-adjusted returns?

GNOM currently has the higher Sharpe Ratio (2.06 vs 1.58), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.